GlassScriptPhysician profile
Stephen R Toothaker
NPI 1033123195
$18,856.59
in general payments reported to CMS, 2019-2025
75 companies · $2,763 in 2025
The $2,763 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $3,737 · 2021: $3,944 · 2022: $1,987 · 2023: $1,695 · 2024: $2,863 · 2025: $2,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,727 · Long Term Medical Supply Or Device Loan: $2,348 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,727.10 |
| Long Term Medical Supply Or Device Loan | $2,348.13 |
| Education | $245.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,561.31 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $3,547.25 | 2019-2025 | |
| G1 Therapeutics, INC. | $1,533.83 | 2021-2023 | Cosela |
| Abbvie INC. | $1,160.90 | 2019-2025 | Venclexta |
| Pfizer INC. | $917.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $727.56 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $654.26 | 2019-2025 | Erleada, Darzalex, Akeega |
| Genzyme Corporation | $448.87 | 2019-2024 | |
| Seagen INC. | $424.01 | 2019-2023 | Tukysa, Adcetris |
| Amgen INC. | $408.75 | 2019-2023 | Lumakras, Kyprolis |
| Daiichi Sankyo INC. | $371.34 | 2019-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $333.34 | 2019-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $302.48 | 2021-2025 | Ojjaara |
| Incyte Corporation | $302.40 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Celgene Corporation | $298.37 | 2019-2025 | Reblozyl, Pomalyst |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Toothaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.